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Abstract
Background: HIV/AIDS has orphaned 11.6 million children in sub-Saharan Africa. Expanded antiretroviral therapy
(ART) use may reduce AIDS orphanhood by decreasing adult mortality and population-level HIV transmission.
Methods: We modeled two scenarios to measure the impact of adult ART use on the incidence of orphanhood in
10 sub-Saharan African countries, from 2009 to 2020. Demographic model data inputs were obtained from cohort
studies, UNAIDS, UN Population Division, WHO and the US Census Bureau.
Results: Compared to current rates of ART uptake, universal ART access averted 4.37 million more AIDS orphans by
year 2020, including 3.15 million maternal, 1.89 million paternal and 0.75 million double orphans. The number of
AIDS orphans averted was highest in South Africa (901.71 thousand) and Nigeria (839.01 thousand), and lowest in
Zimbabwe (86.96 thousand) and Côte d’Ivoire (109.12 thousand).
Conclusion: Universal ART use may significantly reduce orphanhood in sub-Saharan Africa.
Introduction
An estimated 11.6 million children (aged 0 to 17 years)
in sub-Saharan Africa have lost one or both parents due
to human immunodeficiency virus/acquired immune
deficiency syndrome (HIV/AIDS) since the beginning of
the epidemic [1]. Studies suggest that orphans in sub-
Saharan Africa may have poor quality of life and health,
including reduced access to basic material goods and
retention in education [2], and elevated psychological
distress and symptoms of depression [3,4]. Orphans may
be at heightened risk of acquiring HIV due to engage-
ment in early and unprotected sex, and in multiple sex-
ual relationships [5,6]. HIV-infected orphans have
shown to have delayed access to HIV treatment and
care, reduced adherence to HIV treatment, and poor
nutritional status [7-9].
Antiretroviral therapy (ART) has substantially reduced
HIV-related morbidity and mortality worldwide [10].
A growing body of empirical evidence and mathematical
modeling suggests that expanded ART use may also pre-
vent population-level transmission of HIV [11-14]. In
sub-Saharan Africa, 44% (2.925 million) of people clini-
cally eligible for treatment were receiving it at the end of
2008 [15]. Several studies have evaluated the impact of
the AIDS epidemic on orphanhood [15,16]. However,
none to date have examined this in the context of efforts
to expand ART access. We sought to determine to what
extent the varying rates of ART uptake among adults
would prevent the incidence of paternal, maternal and
dual orphans in sub-Saharan Africa, from 2009 to 2020.
Methods
We projected the impact of ART expansion to adults
(15-49 years) on the incidence of paternal, maternal and
dual orphans in 10 sub-Saharan African countries, from
2009 to 2020. We included 10 sub-Saharan African
countries with the highest number of AIDS orphans liv-
ing in 2007: Cote D’Ivoire, Ethiopia, Kenya, Malawi,
Nigeria, South Africa, Uganda, United Republic of
Tanzania, Zambia, and Zimbabwe [1].
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In order to explore the impact of expanded ART use
on orphanhood, we modeled two scenarios. Scenario 1
theoretically assumed that all (100%) HIV infected
adults in the countries under study would receive ART
immediately after year 2008, irrespective of CD4+ cell
count or clinical stage. Scenario 2 assumed that the
number of adults receiving ART remained constant fol-
lowing year 2008, reflecting country-specific rates of
ART uptake and clinical eligibility of people living with
HIV/AIDS in that year [15].
These scenarios were developed using DemProj and
AIM programs within the Spectrum Policy Modeling
System (Futures Group International) software package,
Version 3.34. These programs are designed to produce
information that is useful for policy formulation and
program planning, and have been used by UNAIDS,
UNICEF, USAID and the US Census Bureau to estimate
orphanhood. Detailed descriptions of how Spectrum
models the impact of HIV/AIDS on demographic para-
meters, including background mathematical methodol-
ogy and parameter estimates, are described elsewhere
[17-26]. We followed the prescribed steps for making
HIV/AIDS and orphanhood projections, as outlined in
the USAID Health Policy Initiative’s recent guidelines
[21,23]
Country-specific demographic and epidemiological
model inputs are described in Table 1. All inputs and
parameters used default values in the Spectrum program
developed by the UNAIDS References Group on Esti-
mates, Model and Projections [23]. Where possible,
default values were exchanged with more recent empiri-
cal data, as described below.
Non-HIV demographic inputs
As a first step to developing our AIDS orphanhood pro-
jection model, we conducted a demographic projection.
This involved inputting non-HIV country-specific demo-
graphic estimates, such as population size, fertility and
life expectancy, into the Spectrum Policy Modeling Sys-
tem’s DemProj Program.
Population estimates
Country and age-specific population estimates for each
year were obtained from the United Nations Population
Division. In order to ensure consistency between popula-
tion sizes from our demographic projections and coun-
try-specific census estimates, some of our demographic
inputs were obtained from the US Census Bureau instead
of the United Nations Population Division [27]. This pro-
cess of matching current population estimates with pro-
jection outputs is described elsewhere [23,28,29].
Fertility estimates
We obtained country- and age-specific total fertility
rates (TFR) from the US Census Bureau’s World Popu-
lation Profile [30]. The age distribution of fertility was
estimated using the United Nations Sub-Saharan Africa
model fertility table as outlined by Spectrum.
Mortality estimates
For non-HIV infected individuals, we inputted age-specific
distributions of life expectancy at birth for non-AIDS-
related mortality using the DemProj feature of Spectrum.
HIV-specific inputs
HIV-specific fertility
A review and meta-analysis of 19 studies examining the
population-level impact of HIV on fertility in sub-Saharan
Table 1 Country-specific projection model inputs
Number of single
and dual AIDS
orphans (0-17 yrs),
2007 [44]
HIV
prevalence,
adults 15-49
yrs, 2007 (%)
[44]
Estimated annual
increase in number of
people receiving ART,
2008 [15]
Reported
Number
HIV+ people
receiving
ART, 2008
[15]
Number of HIV+
pregnant women
receiving ART for
PMTCT, 2008 [15]
Estimated Number of
HIV+ pregnant
women who need
ART, 2008
[15]
South
Africa
1,400,000 18.1 192,840 700,500 149,118 200,000
Uganda 1,200,000 5.4 42,492 153,718 41,598 82,000
Nigeria 1,200,000 3.1 68,544 238,659 19,804 210,000
Kenya 1,195,000 7.8 65,880 242,881 59,601 110,000
Zimbabwe 1,000,000 15.3 50,112 147,804 18,756 53,000
United
Rep. of
Tanzania
970,000 6.2 18,768 154,468 70,944 85,000
Ethiopia 650,000 2.1 42 168 132,379 6,354 36,000
Zambia 600,000 15.2 74,436 225,634 41,286 70,000
Malawi 560,000 11.9 46,008 146,657 33,838 57,000
Cote
d’Ivoire
420,000 3.9 13,608 51,833 9,296 22,000
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Africa reported that HIV-positive women not receiving
ART have substantially lower TFR compared to HIV-
negative women. This fertility differential resulted in a
0.37% decrease in population-attributable fertility for each
percentage point of HIV prevalence within a country [31].
In order to incorporate this reduction in TFR in HIV-
infected women into our projections, we used the default
TFR reduction feature in AIM, which inputs age-specific
ratios of fertility for HIV infected women compared to fer-
tility in uninfected women.
HIV incidence
Country-specific HIV incidence inputs for adults (15-49
years) for years 1985 to 2008 were obtained using the
UNAIDS-developed Estimation and Projection Package
(EPP) software, and were converted into percentages
before being inputted into the AIM program [32]. We
assumed HIV was transmitted vertically and through
heterosexual contact. We assumed individuals receiving
ART were on triple combination therapy, or ART. In
Scenario 1, we assumed that individuals receiving ART
had suppressed HIV plasma viral load [14]. Based on
empirical results from a study in Rakai, Uganda, we
assumed that no cases of HIV transmission occurred
among discordant contacts [33], and assumed HIV inci-
dence was zero for every year subsequent to 2008. In
Scenario 2, we assumed HIV incidence remained at the
country-specific rate for 2008, reflecting current rates of
ART uptake [15].
HIV disease progression and survival
We inputted varying disease progression data for Sce-
narios 1 and 2. In Scenario 1, we assumed that all HIV
infected individuals were clinically eligible to receive
ART from end 2008 onward [15]. In Scenario 2, we
assumed that individuals were clinical eligible for ART if
they had CD4 cell count under 350, and that time from
HIV infection to ART eligibility was 3.2 years [23].
For individuals not receiving ART, we assumed
that the median time from HIV infection to AIDS
death, without treatment, was 10.5 years for men and
11.5 years for women [23]. These assumptions were
based on findings from a large multi-country cohort
study in low-resource settings [34]. For adults on ART,
we assumed a survival rate of 0.86 for the first year on
ART. This figure was derived from longitudinal cohort
studies and systematic review of ART patients in low-
incomes settings, and are recommended for use by the
AIM projection model guidelines [23]. The survival rate
of individuals receiving ART gradually increased over a
5-year period, and remained constant at 0.94 for the
duration of the study period, based on a multi-country
prospective cohort across low-income settings [35].
However, due to limitations in Spectrum, the survival
rate for adults on ART was capped at 0.93 in sub-
sequent years.
ART and PMTCT uptake
In Scenario 1, we assumed that all HIV-positive indivi-
duals were receiving ART as of year 2009. In Scenario 2,
we inputted country-specific estimates for annual ART
uptake, based on UNAIDS 2008 figures [15]. We
assumed that antiretroviral (ARV) prophylaxis was una-
vailable to HIV-positive pregnant women in our coun-
tries of interest prior to the year 2004 and that it was
entirely triple ARV prophylaxis. For Scenario 1, we
assumed that all HIV-positive pregnant women received
ARV prophylaxis for prevention of mother-to-child-
transmission (PMTCT) from year 2009 onward. For
Scenario 2, we inputted the percentage of HIV-positive
pregnant women receiving PMTCT between the years
2004 and 2008 obtained from UNAIDS country-specific
epidemiological fact sheets [15,36]. Other inputs under
the Mother to Child Transmission section of AIM were
unaltered.
Outcomes variables
Our primary outcomes were the number of maternal,
paternal and dual AIDS orphans in each country at year
2020 following varying scenarios of ART uptake. Mater-
nal and paternal AIDS orphans were defined as children
under the age of 17 who have lost either their mother
or father to AIDS. Dual orphans are children who have
lost both parents to AIDS [23].
Projection and Calibration of Model
We ran each country’s DemProj and AIM input data
together from Spectrum to project the number of AIDS
orphans incurred in each year. In order to calibrate our
model, we ran DemProj and AIM programs for each
country, using the above inputted data and parameters,
from 1985 to end 2007. We verified the accuracy of our
AIDS orphans projections by comparing our results for
2007 to the 2007 AIDS orphan estimate published in
UNAIDS country-specific epidemiological fact sheets
[36]. In order to identify the best fit for our model, as
described in previous sections, we modified assumptions
regarding population size and HIV survival rates using
published ranges for census [23,27-29] and empirical
cohort [23,34,35] data.
Results
Table 2 presents the projected number of maternal,
paternal, double and total AIDS orphans averted, per
sub-Saharan African country, by varying levels of ART
uptake at year 2020. Scenario 1, in which adults had uni-
versal ART access, averted a cumulative total of 4.37 mil-
lion more AIDS orphans by year 2020 than Scenario 2,
where ART access was expanded gradually. This included
an estimated 3.15 million maternal orphans, 1.89 million
paternal orphans and 748,320 double orphans.
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Countries with the largest number of AIDS orphans
averted over the study period included South Africa
(901,705), Nigeria (839,014), and Kenya (717,382).
Countries with the least number of AIDS orphans
averted were Zimbabwe (86,961), Malawi (262,428) and
Côte d’Ivoire (109,121). The number of maternal
orphans averted was higher than the number of paternal
orphans averted in all countries: South Africa (879,336
versus 361,599), Uganda (188,307 versus 143,526),
Nigeria (525,277 versus 336,117), Kenya (484, 738 versus
324,532), Zimbabwe (75,518 versus 23,108), Tanzania
(334,028 versus 273,870), Ethiopia (180,877 versus
125,483), Zambia (228,301 versus 128,468), Malawi
(179,246 versus 125,327), and Cote d’Ivoire (72,609
versus 46,269)
Figure 1 describes the number of maternal, paternal,
and double AIDS orphans averted at year 2020, by
country, due to universal ART access. It shows that the
number of total AIDS orphans averted by increasing
ART access would be highest in South Africa (901,705)
and lowest in Zimbabwe (86,961).
Figure 2 shows the number of orphans incurred in
Scenario 1 and Scenario 2 for each of the 10 sub-
Saharan African countries.
Discussion
Results of this study highlight the positive impact that
expanded ART may have in sub-Saharan African coun-
tries already burdened with high numbers of AIDS
orphans. We found that achieving universal ART uptake
among adults may avert over 4 million maternal, pater-
nal and double AIDS orphans over the next 10 years.
These findings underscore the critical role of ART for
reducing harms associated with AIDS orphanhood in
countries such as South Africa and Nigeria, where
annual rates of ART uptake were projected to have the
greatest impact. They also draw attention to the need
for accelerated ART expansion in countries, such as
Zimbabwe and Uganda, where low annual rates of ART
expansion will have a comparatively reduced impact on
orphanhood averted.
These results have important implications for the
health and quality of life of children in sub-Saharan
Africa and other HIV-endemic areas. Studies in
Zimbabwe and Namibia have found that orphans experi-
ence elevated psychological distress, including symptoms
of depression [3,4] Across Africa, orphans appear to
have limited access to basic material goods and educa-
tion, and tend to drop out of school more than non-
orphans [1]. Studies in Zimbabwe have found that
orphans, and particularly maternal orphans, are at ele-
vated risk of acquiring HIV since they engage in early
and unprotected sex, and have multiple sexual partners
[5,6]. HIV-positive orphans have shown to have delayed
access to HIV treatment and care in Uganda, reduced
adherence to ART in Kenya, and poor nutritional status
in Thailand [7-9]. We found that universal ART access
would have a particularly positive impact on reducing
Table 2 Projected number of maternal, paternal, and double AIDS orphans incurred and averted, per sub-Saharan
African country, at year 2020
South
Africa
Uganda Nigeria Kenya Zimbabwe Tanzania Ethiopia Zambia Malawi Cote
d’Ivoire
Orphans incurred with universal ART
access
Maternal 1,379,420 379,000 887,810 691,022 286,624 549,876 316,258 413,474 312,314 151,461
Paternal 1,452,297 592,386 1,165,760 913,492 410,784 735,112 421,703 535,465 432,220 241,890
Double 688,762 151,493 201,155 378,776 171,243 233,989 77,547 224,763 126,391 77,932
All 2,258,756 857,842 1,982,969 1,288,338 561,259 1,096,206 693,419 769,052 632,518 325,891
Orphans incurred by sustaining
current ART access
Maternal 2,258,756 567,307 1,413,087 1,175,760 362,142 883,904 497,135 641,775 491,560 224,070
Paternal 1,813,896 735,912 1,501,877 1,238,024 433,892 1,008,982 547,186 663,933 557,547 288,159
Double 940,552 192,112 282,339 503,190 188,051 318,425 98,724 290,848 174,617 91,513
All 3,160,461 1,163,017 2,821,983 2,005,720 648,220 1,641,721 994,221 1,075,967 894,946 435,012
Orphans averted with universal ART
access
Maternal 879,336 188,307 525,277 484,738 75,518 334,028 180,877 228,301 179,246 72,609
Paternal 361,599 143,526 336,117 324,532 23,108 273,870 125,483 128,468 125,327 46,269
Double 251,790 40,619 81,184 124,414 16,808 84,436 21,177 66,085 48,226 13,581
All 901,705 305,175 839,014 717,382 86,961 545,515 300,802 306,915 262,428 109,121
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the number o maternal AIDS orphans in sub-Saharan
Africa. Several studies have evaluated the impact of
AIDS-specific maternal mortality on orphanhood
[16,21]. However, none have explored this within the
context of the expansion of ART access.
Strengths and limitations of our model pertain to the
Spectrum program used. Spectrum is used by UNAIDS
to estimate HIV-prevalence, mortality, ART needs and
orphanhood. One strength of this software is that it
enables the inputting of country, age and sex-specific
Figure 1 Maternal, paternal, and double AIDS orphans averted due to universal antiretroviral uptake in ten Sub-Saharan African
countries by year 2020.
Figure 2 Total number of AIDS orphans incurred in Scenario 1 (Universal ART uptake) and Scenario 2 (Sustaining current rate of ART
access) in 10 Sub-Saharan African countries by year 2020.
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HIV prevalence values. In doing so, it allows modellers
to consider the heterogeneity of HIV prevalence, both
between and within, countries under study. However,
we assumed that HIV prevalence for each country
would remain constant after year 2008 due to the lack
of UNAIDS data beyond that year. Since high HIV pre-
valence is correlated with high orphanhood, and since
prevalence is declining in many sub-Saharan African
countries, this assumption about a stable HIV preva-
lence after year 2008 may led to an overestimation of
AIDS orphanhood. Use of the Estimation and Projection
Package (EPP) in conjunction with Spectrum may have
rectified this issue. Developers of Spectrum previously
tested and validated the age and sex-specific HIV preva-
lence values for several countries included in our analy-
sis (e.g. Kenya, Tanzania and Zambia) [17]. The
verification of country-specific projection estimates
against demographic health survey findings allowed for
the generation of prevalence values that are as close as
possible to actual epidemiological trends.
Program limitations relate to the detailed methodology
for calculating AIDS orphans in the presence and
absence of ART. For instance, there is little quantitative
information regarding the effect of ART on female ferti-
lity and its effect on orphanhood. While there is an
input for adult and child survival on ART, these values
are fixed, and are based on a single study [19]. Another
orphan modeling study assumed that women receiving
ARVs had a fertility rate 50% lower than women not
receiving treatment [37]. They also assumed that indivi-
duals initiating ART had a median survival 50% higher
than those not on therapy. Yet, these assumptions have
little empirical evidence that lend support. However,
when comparing their results, the number of maternal
orphans incurred in South Africa with ART intervention
was similar to our findings, indicating that their metho-
dology paralleled our own.
Discrepancies between Spectrum-based and empirical
household survey estimates of orphanhood have been
previously identified. Projected estimates of orphanhood
have tended to be higher than empirical approximates
[28,29]. This may be due either to several factors includ-
ing under-reporting of deaths in household surveys,
erroneously high non-AIDS related mortality rates in
projection models, or the fact that foster parents some-
times claim adopted children as their natural children
[28,29]. Given these reported discrepancies, it is possible
that our projection model may have also over-estimated
the number of orphans incurred and averted in the sub-
Saharan African countries under study.
This study only indirectly considered the impact of
non-adherence on HIV outcomes by means of inputting
empirically obtained mortality rates. A closer examina-
tion of adherence would have been valuable given the
association between adherence and mortality [38].
A systematic review of 33 cohort studies in sub-Saharan
Africa found that on average one-year patient retention
in ART programs was 75%, with patient attrition caused
by loss to follow-up or death [39]. A more recent cohort
study of 48,338 Médecins Sans Frontières patients found
median patient retention to be 86% at one year [40].
These empirical studies suggest adult survival rates may
be lower than what we inputted in our model, and that
the projected number of orphans averted may also be
slightly lower.
Another potential limitation of our analysis relates to
our assumption that the TFR of women on ART would
be comparable with that of the general population,
while the TFR of women not on ART is depressed
[41,42]. A recent study from Uganda has shown, how-
ever, that women on ART were 44% less likely to
become pregnant and 70% less likely to give birth than
HIV-positive women not on ART in the three years
prior to the study [43]. It remains to be determined if
this fertility differential remains constant over the course
of the reproductive lifespan. In this case, our assumption
will have slightly overestimated the TFR of women on
ART, thereby overestimating the number of orphans
averted through expanded access to ART. Nevertheless,
as shown in the case of South Africa, even when the
TFR is low, high HIV prevalence and high rates of ART
use still result in a high number of maternal orphans
averted. Other potential limitations in our study include
our assumption that adult and child ART survival was
the same for all countries may not be reflective of actual
country rates.
Conclusion
Our projection model strongly argues that expanded
access to HIV treatment will have immediate preventive
impact on the health and welfare of children in sub-
Saharan Africa. If we are to make important gains in
livelihood for future generations in Africa, expanding
access to ART should be of paramount importance.
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